Trial Profile
The GLORIA Study: A Phase 3, Randomized, Open-Label Study of the Anti-Globo H Vaccine Adagloxad Simolenin (OBI-822)/OBI-821 in the Adjuvant Treatment of Patients With High Risk, Early Stage Globo H-Positive Triple Negative Breast Cancer
Status:
Recruiting
Phase of Trial:
Phase III
Latest Information Update: 01 Mar 2024
Price :
$35
*
At a glance
- Drugs Adagloxad simolenin (Primary) ; OPT 821 (Primary) ; Capecitabine; Platinum complexes
- Indications Carcinoma; Early breast cancer; HER2 negative breast cancer; Male breast cancer; Triple negative breast cancer
- Focus Registrational; Therapeutic Use
- Acronyms GLORIA
- Sponsors OBI Pharma
- 07 Jun 2022 Trial design presented at the 58th Annual Meeting of the American Society of Clinical Oncology
- 17 May 2022 According to an OBI Pharma media release, data from this study will be presented at the American Society of Clinical Oncology (ASCO) meeting.
- 11 Dec 2020 Protocol of this study has been amended to change the study design from double-blind, placebo control to open-label, standard of care and to allow concurrent adjuvant single agent chemotherapy (capecitabine and/or platinum).